Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prime-boost pneumococcal vaccination in first-line rituximab-treated diffuse large B-cell lymphoma
2019-002542-20Phase 3Completed
- Sponsor
- CHRU Tours
- Start
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pneumococcal 13-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (3 arms), sponsored by CHRU Tours. Started Jul 2019; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2019-002542-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002542-20.